Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 76587, held by Sun Pharma Canada. Alclometasone Dipropionate.
As of Nov 21, 2026, ANDA 76587 (Alclometasone Dipropionate), held by Sun Pharma Canada, was first approved by FDA on Sep 15, 2005, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Alclometasone Dipropionate Cream USP, 0.05% is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Alclometasone dipropionate cream may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see PRECAUTIONS: Pediatric Use ). Since the safety and efficacy of alclometasone dipropionate cream have not been established in pediatric patients below 1 year of age, their use in this age-group is not recommended.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 15, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alclometasone Dipropionate0.05% · cream;topical | Alclometasone Dipropionate | Rx |
| Jul 26, 2011 | Supplement 3Labeling | Approved | None posted |
| Sep 15, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters